The CKB2 ortholog, CSNK2B (Zhang et al. 2015; Chua et al. 2017; Dotan et al. 2001), is over-expressed in several liver cancers and therapeutics are currently in clinical trial (Gray et al. 2014; Li et al. 2017; Trembley et al. 2017). Here, CSNK2B is linked to liver cancer.